Ítem
Acceso Abierto

Can appropriate systemic treatment help protect the cornea in patients with rheumatoid arthritis? A multidisciplinary approach to autoimmune ocular involvement

Mostrar el registro sencillo de la publicación
dc.creatorAmador-Patarroyo, Manuel Jspa
dc.creatorJalil-Florencia, Emiliospa
dc.creatorOtero-Marquez, Oscarspa
dc.creatorMolano González, Nicolás
dc.creatorMantilla, Ruben Dspa
dc.creatorRojas-Villarraga, Adrianaspa
dc.creatorAnaya, Juan-Manuelspa
dc.creatorBarraquer-Coll, Carmenspa
dc.date.accessioned2020-05-26T00:05:19Z
dc.date.available2020-05-26T00:05:19Z
dc.date.created2018spa
dc.description.abstractPurpose: To correlate rheumatologic with ophthalmic and laboratory findings in patients with rheumatoid arthritis (RA) to identify what effect these have on development of ocular disease. Methods: This is a cross-sectional study of 172 eyes of 86 patients with RA. Patients were examined by a group of rheumatologists. Sociodemographic, clinical, and laboratory data were collected. All patients underwent complete ophthalmologic examination including corneal topography and endothelial cell count. Results: There was no significant correlation between RA-negative prognostic indicators (NPIs) and pathologic corneal findings. Patients using disease-modifying antirheumatic drugs (DMARDs) and antimalarial drugs had greater corneal volumes (mean difference 8.51 mm3, 90% confidence interval [CI], 3.98-13.04, P = 0.004; and 2.24, 90% CI, 0.32-4.54, P = 0.048, respectively). Patients using azathioprine had lower endothelial cell counts compared with those using other drugs (mean difference 180 cells/mm2, 90% CI, 69-291, P = 0.008). Patients using biologic DMARDs had better tear osmolarity values (between 280 and 300 mOsm/L) than patients not using them (mean difference 14.3 mOsm/L, P = 0.022). There was no correlation between NPIs of RA and positive keratoconus screening indices (Spearman correlation OD -0.013, P = 0.91; OS -0.033, P = 0.76). Conclusions: There was no clear correlation between RA-NPIs and pathologic corneal findings in our study. DMARDs treatment may help maintain corneal integrity in our patients and prevented collagenolytic manifestations of RA. Other medications such as azathioprine should be used carefully, as endothelial damage may potentially occur. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1097/ICO.0000000000001467
dc.identifier.issn2773740
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23778
dc.language.isoengspa
dc.publisherLippincott Williams and Wilkinsspa
dc.relation.citationEndPage241
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage235
dc.relation.citationTitleCornea
dc.relation.citationVolumeVol. 37
dc.relation.ispartofCornea, ISSN:2773740, Vol.37, No.2 (2018); pp. 235-241spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85043712720&doi=10.1097%2fICO.0000000000001467&partnerID=40&md5=7646285cb6122f81ff367d1ac4e4fe88spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAbataceptspa
dc.subject.keywordrheumatoideng
dc.subject.keywordAntimalarial agentspa
dc.subject.keywordAzathioprinespa
dc.subject.keywordCorticosteroidspa
dc.subject.keywordDisease modifying antirheumatic drugspa
dc.subject.keywordLeflunomidespa
dc.subject.keywordMethotrexatespa
dc.subject.keywordRheumatoid factorspa
dc.subject.keywordSalazosulfapyridinespa
dc.subject.keywordTocilizumabspa
dc.subject.keywordTumor necrosis factor inhibitorspa
dc.subject.keywordAntirheumatic agentspa
dc.subject.keywordImmunosuppressive agentspa
dc.subject.keywordArticlespa
dc.subject.keywordCell countspa
dc.subject.keywordCorneaspa
dc.subject.keywordCornea endotheliumspa
dc.subject.keywordCross-sectional studyspa
dc.subject.keywordDisease activity scorespa
dc.subject.keywordDisease durationspa
dc.subject.keywordEye diseasespa
dc.subject.keywordEye protectionspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordKeratoconusspa
dc.subject.keywordKeratometryspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordOphthalmologyspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRheumatoid arthritisspa
dc.subject.keywordScleritisspa
dc.subject.keywordSystemic therapyspa
dc.subject.keywordTear osmolarityspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAnalysis of variancespa
dc.subject.keywordChemistryspa
dc.subject.keywordComplicationspa
dc.subject.keywordCorneaspa
dc.subject.keywordCornea diseasespa
dc.subject.keywordCytologyspa
dc.subject.keywordEndothelium cellspa
dc.subject.keywordLacrimal fluidspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPathologyspa
dc.subject.keywordRheumatoid arthritisspa
dc.subject.keywordRisk factorspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAnalysis of variancespa
dc.subject.keywordAntirheumatic agentsspa
dc.subject.keywordArthritiseng
dc.subject.keywordCell countspa
dc.subject.keywordCorneaspa
dc.subject.keywordCorneal diseasesspa
dc.subject.keywordCorneal topographyspa
dc.subject.keywordCross-sectional studiesspa
dc.subject.keywordEndothelial cellsspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordImmunosuppressive agentsspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRisk factorsspa
dc.subject.keywordTearsspa
dc.subject.keywordCollagenolysisspa
dc.subject.keywordCorneaspa
dc.subject.keywordDisease-modifying antirheumatic drugsspa
dc.subject.keywordKeratoconusspa
dc.subject.keywordRheumatoid arthritisspa
dc.titleCan appropriate systemic treatment help protect the cornea in patients with rheumatoid arthritis? A multidisciplinary approach to autoimmune ocular involvementspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Can_Appropriate_Systemic_Treatment_Help_Protect-18.pdf
Tamaño:
281.75 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos